We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
BIO-RAD LABORATORIES

Download Mobile App




Pneumococcal Immune Status Accurately Determined in Saliva Samples

By LabMedica International staff writers
Posted on 27 Dec 2016
Print article
Image: A fluorescent micrograph of Streptococcus pneumoniae in spinal fluid (Photo courtesy of the CDC).
Image: A fluorescent micrograph of Streptococcus pneumoniae in spinal fluid (Photo courtesy of the CDC).
Measurement of levels of antibodies against 12 Streptococcus pneumoniae antigens in saliva was shown to provide as accurate an indication of immune status against this organism as was determination of antibody levels in blood serum.

The objective of a study carried out at the University of Birmingham United Kingdom) was to assess if levels of anti-pneumococcal (Pn) antibodies in saliva reflected concentrations in serum and to determine whether saliva could accurately identify protective concentrations in serum.

Toward this end the investigators employed a multiplex assay, the BioRad Laboratories (Hercules, CA, USA) Luminex-200, Bioplex System, that simultaneously measured antibody concentrations against 12 Pn antigens, to determine IgG, IgA, and IgM antibody levels in paired saliva and serum samples against 12 Pn polysaccharide antigens in 72 healthy adults.

Results revealed that antibody levels in saliva correlated positively with serum across immunoglobulin classes, most strongly for IgA. Individuals who had protective antibody levels in serum demonstrated significantly higher IgG and IgA salivary antibody concentrations and secretion rates. Salivary IgG and IgA Pn antibodies were able to distinguish between those with/without protective levels in serum for the majority of serotypes. Salivary IgM antibodies were not able to differentiate protective status.

First author Dr. Jennifer Heaney, a researcher in immunity and infection at the University of Birmingham, said, "Protection against bacterial infection is usually inferred by measuring antibody levels in blood serum. But taking blood samples involves a number of logistical considerations and may not always be feasible, especially in developing countries or where children are involved. Saliva sampling is non-invasive, requires no specialist training or equipment, and may be more cost-effective. The suggestion that antibody levels in saliva may be indicative of those in serum therefore has important implications for markers of immunity and vaccination in many parts of the world. This research highlights the need for larger studies further to investigate the potential of saliva testing as a tool to assess immunity."

The study was published in the December 12, 2016, online edition of the journal Biomarkers.

Related Links:
University of Birmingham
BioRad Laboratories

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Real-time PCR System
GentierX3 Series

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Molecular Diagnostics

view channel
Image: A network of inflammatory molecules may act as biomarker for risk of future cerebrovascular disease (Photo courtesy of 123RF)

Simple Blood Test Could Enable First Quantitative Assessments for Future Cerebrovascular Disease

Cerebral small vessel disease is a common cause of stroke and cognitive decline, particularly in the elderly. Presently, assessing the risk for cerebral vascular diseases involves using a mix of diagnostic... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: Exosomes can be a promising biomarker for cellular rejection after organ transplant (Photo courtesy of Nicolas Primola/Shutterstock)

Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies

Transplanted organs constantly face the risk of being rejected by the recipient's immune system which differentiates self from non-self using T cells and B cells. T cells are commonly associated with acute... Read more

Pathology

view channel
Image: The Aperio GT 450 DX has received US FDA 510(k) clearance (Photo courtesy of Leica Biosystems)

Use of DICOM Images for Pathology Diagnostics Marks Significant Step towards Standardization

Digital pathology is rapidly becoming a key aspect of modern healthcare, transforming the practice of pathology as laboratories worldwide adopt this advanced technology. Digital pathology systems allow... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.